Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fecal microbiota transplant (FIMABIS)
- Development stage
- Unknown
- Lead developer
- Fundación IMABIS
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
This fecal microbiota transplant (FMT) is an investigational biological therapy developed by the Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (FIMABIS) for the treatment of type 2 diabetes mellitus and obesity. The intervention involves the oral administration of lyophilized fecal material derived from healthy, lean donors, encapsulated in gelatin capsules. The primary objective is to restore a healthy gut microbiota composition in patients with metabolic dysfunction, thereby improving insulin sensitivity and glycemic control. In the EPIGEN-MICROBIOTA (NCT05076656) Phase II trial, the therapy was evaluated for its ability to modify the intestinal bacterial community and impact epigenetic markers associated with adipose tissue dysfunction in patients already receiving metformin.
- Other names
- FMTlyophilized fecal microbiota transplantFecal microbiota transplant (FMT)
Beyond the preview
Go deeper on Fecal microbiota transplant (FIMABIS).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fecal microbiota transplant (FIMABIS).